狄诺塞麦:治疗绝经期女性骨质疏松的新希望

狄诺塞麦是目前用于治疗绝经期骨质疏松的第一种单克隆抗体药物.它能与细胞核因子-κB受体活化因子配体(RANKL)结合,通过抑制破骨细胞的产生、功能和存活,减少骨吸收达到治疗作用.临床试验显示,在绝经后骨质疏松妇女中,狄诺塞麦增加骨密度(BMD)和降低骨折风险的作用优于安慰剂和阿仑膦酸,不良反应与安慰剂和阿仑膦酸相当.药...

Denosumab: a promise for treatment of postmenopausal osteoporosis

Denosumab is the first monoclonal antibody agency for the treatment of postmenopausal osteoporosis recently. Denosumab binds to receptor activator of nuclear factor-κB ligand (RANKL) and inhibits bone resorption by means of reducing the formation,function and survival of osteoclasts. Clinical trials have shown that denosumab increased bone mineral density ( BMD) and reduced fracture risk superior to placebo and alendronate in postmenopausal osteoporosis women. The profile of adverse events in treatment is similar to placebo and alendronate. The pharmacoeconomic studies of denosumab have shown that denosumab may be an alternative to oral osteoporosis treatment because of its better cost effective ratio. There is a promise for denosumab to be a new option in treatment of postmenopausal osteoporosis.